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Abstract
The neurite outgrowth inhibitor, Nogo-A, has been shown to be overexpressed in skeletal muscle in amyotrophic lateral
sclerosis (ALS); it is both a potential biomarker and therapeutic target. We performed a double-blind, two-part, dose-
escalation study, in subjects with ALS, assessing safety, pharmacokinetics (PK) and functional effects of ozanezumab, a
humanized monoclonal antibody against Nogo-A. In Part 1, 40 subjects were randomized (3:1) to receive single dose
intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg) or placebo. In Part 2, 36 subjects were randomized (3:1) to receive two
repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg) or placebo, approximately 4 weeks apart. The primary
endpoints were safety and tolerability (adverse events [AEs], vital signs, electrocardiogram (ECG), and clinical laboratory
tests). Secondary endpoints included PK, immunogenicity, functional endpoints (clinical and electrophysiological), and
biomarker parameters. Overall, ozanezumab treatment (0.01–15 mg/kg) was well tolerated. The overall incidence of AEs in
the repeat dose 2.5 mg/kg and 15 mg/kg ozanezumab groups was higher than in the repeat dose placebo group and
repeat dose 0.5 mg/kg ozanezumab group. The majority were considered not related to study drug by the investigators. Six
serious AEs were reported in three subjects receiving ozanezumab; none were considered related to study drug. No study
drug-related patterns were identified for ECG, laboratory, or vital signs parameters. One subject (repeat dose 15 mg/kg
ozanezumab) showed a weak, positive anti-ozanezumab-antibody result. PK results were generally consistent with
monoclonal antibody treatments. No apparent treatment effects were observed for functional endpoints or muscle
biomarkers. Immunohistochemical staining showed dose-dependent co-localization of ozanezumab with Nogo-A in skeletal
muscle. In conclusion, single and repeat dose ozanezumab treatment was well tolerated and demonstrated co-localization
at the site of action. These findings support future studies with ozanezumab in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by selective
and progressive loss of upper motor neurons of the motor cortex
and lower motor neurons of the brainstem and spinal cord.[1–3]
The main manifestations of ALS are progressive widespread
muscle weakness and atrophy, leading to severe motor disability
that affects speech, swallowing, respiratory function, and the
extremities.[4] Cognitive impairment, predominantly in the form
of executive dysfunction, may be detected in around 50% of
patients, with up to 15% experiencing frontotemporal demen-
tia.[5] Most patients die within 5 years of onset.[1,4]
Excitotoxicity, i.e. an excessive drive of glutamate, is considered
to be one of the mechanisms of neurodegeneration in ALS.[6]
Riluzole, the only currently approved drug that alters survival in
ALS, is thought to reduce excessive glutamatergic drive on
neurons.[3,7] Although the exact mechanism of action of riluzole
is unclear, it is likely to involve several components, including
inhibition of glutamate release, blockade of calcium and sodium
channels, modulation of c-Aminobutyric acid (GABA) transmis-
sion, as well as effects on N-Methyl-D-aspartate (NMDA) or a-
Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors.[7–9]
Nogo-A, a negative regulator of neuronal growth, is a potent
neurite outgrowth inhibitor in the adult central nervous system
and is expressed by oligodendrocytes.[10,11] Outside the central
nervous system Nogo-A is overexpressed in the skeletal muscle of
the superoxide dismutase 1 (SOD1) transgenic mouse model of
ALS, as well as in human skeletal muscle, as demonstrated in
biopsies taken from patients with ALS.[12] Nogo-A expression in
skeletal muscle has been proposed as an early diagnostic
biomarker of ALS, with the level of expression reported to
correlate with disease severity.[12–14] This view is challenged by
reports suggesting that Nogo-A is a marker of muscle denervation
rather than ALS specifically, noted to be up-regulated in muscle in
preclinical denervation models and in muscle biopsies from
subjects with a range of myopathies and peripheral neuropa-
thies.[15–18] In the SOD1 transgenic mouse genetic ablation of
Nogo-A prolonged survival and reduced muscle denervation,[19]
while overexpression of Nogo-A in muscle fibers of mice induced
neuromuscular junction instability and promoted denervation.[19]
There is therefore a strong rationale for testing antibodies against
Nogo-A in ALS. It is anticipated that blockade of Nogo-A may
inhibit neurite retraction and potentially slow the axonal
degeneration pattern in lower motor neurons that begins at the
neuromuscular junction.[20] This may enhance motor neurone-
muscle coupling, leading to functional improvement and survival
benefits in patients with ALS.
Ozanezumab (GSK1223249: GlaxoSmithKline) is a humanized
monoclonal antibody against Nogo-A, which is currently being
investigated for the treatment of ALS. Ozanezumab has two
possible modes of action: preventing binding of Nogo-A to the
Nogo-A receptor and/or Nogo-A down-regulation by antibody-
induced internalization of cell surface Nogo-A.[21]
Given that the anticipated mechanism of action of ozanezumab
is via Nogo-A, which is not appreciably expressed in skeletal
muscle under physiological conditions but is overexpressed in
ALS, it was felt that conduct of a study in healthy subjects would
not adequately reveal the potential risks or effects of treatment.
Therefore, the first-in-human, Phase I/IIa study presented here
was performed in subjects with ALS to assess the safety,
pharmacokinetic (PK), and functional and biomarker effects of
ozanezumab.
Methods
Study design
This was a randomized, placebo-controlled, double-blind, single
and repeat dose-escalation, two-part study in subjects with ALS,
conducted at 11 sites in France, Italy, the UK, and the USA,
between May 2009 and September 2011. Screening took place
within 28 days of the first dose of investigational product. In Part
1, escalating single doses (SD) of ozanezumab (0.01, 0.1, 1, 5, or
15 mg/kg administered intravenously [IV]), were evaluated in five
sequential subject cohorts (8 subjects per cohort, randomized 3:1
to receive ozanezumab or placebo). Part 2 was also of a sequential
dose-escalating design: 36 subjects across three cohorts (12 subjects
per cohort) were randomized (3:1) to receive two repeat doses (RD)
of ozanezumab (0.5, 2.5, or 15 mg/kg administered IV) or
placebo, approximately 4 weeks apart. IV infusions were given
over 60 minutes except for the 0.01 mg/kg dose, which was given
over 11.2 minutes. Key safety data were reviewed by a blinded
Dose Escalation Committee (comprising GlaxoSmithKline staff
and an external expert neurologist who was experienced in ALS)
before proceeding to the next dosing cohort. To ensure tolerability
before proceeding, the first four subjects in all cohorts of Part 1
and the first cohort of Part 2 received treatment on consecutive
days, so that only one subject was randomized and dosed within
any 24-hour period. Dosing of all other subjects was not staggered.
The follow-up period was at least 12 weeks for all subjects.
Subjects in Part 2 were followed-up for 16 weeks and subjects
receiving 15 mg/kg ozanezumab were followed-up for immuno-
genicity for 16–20 weeks.
Ethics statement
The study protocol, protocol amendments, and informed
consent were approved by a national, regional or investigational
center ethics committee or an institutional review board (IRB), at
each of the participating sites: Comite´ de Protection des Personnes
Ile-de-France VI, Hoˆpital La Pitie´-Salpeˆtrie`re, Paris, France;
Comitato Etico per la Sperimentazione, Azienda Ospedaliera,
Universitaria Integrata di Verona, Italy; Guy’s Research Ethics
Committee, St. Thomas Hospital, London, UK; Carolinas
Healthcare System IRB, North Carolina; Wake Forest University
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Health Sciences, IRB, North Carolina; Johns Hopkins Medicine
IRBs, Maryland; Western IRB, Washington; IRB, Weill Cornell
Medical Center, New York; and IRB for the Protection of Human
Subjects, SUNY Upstate Medical University, New York, USA.
This study was conducted in accordance with Good Clinical
Practice and the guiding principles of the Declaration of Helsinki,
and all subjects provided written informed consent. This study is
registered at clinicaltrials.gov/(NCT00875446) and at http://
www.gsk-clinicalstudyregister.com (GSK ID 111330). The proto-
col for this trial and supporting CONSORT checklist are available
as supporting information; see Checklist S1 and Protocol S1.
Randomization and masking
Subjects in each cohort were centrally randomized across all
sites via an Interactive Voice Response System. The randomiza-
tion schedule was computer-generated using the validated in-
house RandAll system. Infusions were prepared by a non-blinded
pharmacist at the study site and infusion lines were masked in
order to maintain the study blind.
Patients
Eligible subjects were male or female of non-childbearing
potential, 18–80 years of age, with a diagnosis of possible,
laboratory-supported probable, probable or definite familial or
sporadic ALS according to The Revised El Escorial diagnostic
criteria,[22] and onset of muscle weakness within 60 months of
study entry. Each subject was only allowed to participate in one
part of the study. Subjects were also required to have a slow
inspiratory vital capacity (SVC) $70% of predicted (changed by
protocol amendment to include those with SVC ,70% at the
discretion of the investigator, as long as they did not show
respiratory insufficiency). Medications (including riluzole) were
required to have been stable within 28 days prior to dosing. Main
exclusion criteria were: neuromuscular disorders (in addition to
ALS, that could have impacted the study outcomes), dementia or
psychiatric illnesses, that may have affected either outcome
measures or patient understanding and/or compliance with the
study requirements and procedures; positive alcohol or drugs tests
at screening or a history of excessive alcohol consumption;
vaccination within 3 weeks of study drug administration (originally
2 months; changed by protocol amendment); exposure to a clinical
trial product within 6 months or exposure to four investigational
products within 12 months of study drug administration; for
patients undergoing muscle biopsies, wasted deltoids (Medical
Research Council [MRC] score #2), and normal deltoids (MRC
score 5) or those at a higher risk of bleeding complications.
Endpoints and assessments
The primary endpoint was the safety and tolerability of SD or
RD ozanezumab in subjects with ALS. Secondary endpoints
included PK, immunogenicity, functional (clinical and electro-
physiological) and biomarker analyses. Assessment timings are
provided in Tables S1 and S2.
Safety. Adverse events (AEs), serious AEs (SAEs), electrocar-
diography (ECG), vital signs, and clinical laboratory tests
(hematology and biochemistry) were monitored and assessed.
ECG data for all subjects were centrally analyzed and reviewed by
an independent cardiologist. Evaluation of safety signals also
included any adverse effects on functional endpoints (clinical and
electrophysiological) or immunogenicity.
Pharmacokinetics. Evaluation of plasma ozanezumab PK
was performed at various time points in both parts of the study
(Tables S1 and S2). PK parameters included: maximum observed
plasma concentration (Cmax); area under the plasma concentra-
tion-time curve up to Week 4 and infinity (AUC0–Week 4 and
AUC0–‘, respectively); terminal phase half-life; and clearance.
An assessment of ozanezumab concentrations was performed on
skeletal muscle biopsies from subjects in Cohorts 3 and 5 from Part
1 and from all cohorts in Part 2.
Immunogenicity. Immunogenicity was assessed at various
time points (Tables S1 and S2) from serum samples using an
immune-electrochemiluminescent assay.
Functional endpoints. Functional endpoints (clinical and
electrophysiological) were: ALS functional rating scale-revised
(ALSFRS-R) score;[23]% predicted SVC;[24] manual muscle
strength test (MMT);[25] and two motor unit number estimation
(MUNE) endpoints (estimated number of motor units and mean
single motor unit potential amplitude).[26]
Biomarkers. Exploratory biomarker analyses were per-
formed on muscle biopsies, taken from the weaker deltoid muscle
(grade 3 or 4 on the MRC scale) and plasma samples at pre- and
post-dose. Ribonucleic acid (RNA) expression was assessed in
muscle biopsy samples using quantitative reverse transcriptase
polymerase chain reaction/whole genome microarray, while the
expression of Nogo-A protein in muscle and plasma was analyzed
using enzyme-linked chemiluminescence.
Frozen sections of muscle biopsies were examined by immuno-
histochemistry (IHC) and laser scanning cytometry (LSC).
Expression of Nogo-A protein, ozanezumab, and gamma
sarcoglycan was measured to quantify the co-localization of
Nogo-A and ozanezumab within the muscle plasma membrane
using LSC. Detailed methods are available in Methods S1 and
Table S3.
Pharmacokinetic/functional endpoint relationship. Gra-
phical exploration of a potential exposure–response relationship for
ozanezumab was performed for ALSFRS-R score (monthly rate of
decline) at each post-baseline visit, using average plasma ozanezu-
mab concentration over the dosing interval as a measure of
exposure.
Statistical analyses
There was no formal calculation of power or sample size for this
early phase clinical trial. The sample size was based on safety and
feasibility. Safety data, drug concentration data, and PK
parameters were presented in tabular and/or graphical format
and summarized descriptively. All statistical analyses were
performed in SAS software version 9.1.3 or higher. No formal
hypotheses were tested. Point estimates and corresponding 95%
confidence intervals were constructed for the difference between
the mean of ozanezumab and the mean of placebo, calculated as
m(ozanezumab) - m(placebo).
A mixed effects analysis of variance model was used to assess the
dose proportionality of Cmax, AUC0–Week 4, and AUC0–‘, for SD
and RD ozanezumab. Estimates of slope with respect to log (dose)
together with 90% confidence intervals were used to quantify the
degree of non-proportionality.
For ALSFRS-R and MMT, the slope (monthly rate of decline)
was modelled using a random coefficients regression model. For %
predicted SVC and both MUNE endpoints, the percentage
change from screening was modeled using a mixed effects repeated
measures model. Planned comparisons were made between each
dose and placebo.
Results
Study population
Of the 76 subjects who were enrolled, 71 completed the study
(53 on ozanezumab, 18 on placebo). Subject disposition and
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baseline characteristics are presented in Figure 1. Across all
subjects, the mean age was 58 years, mean body mass index was
26.2 kg/m2, and the majority of subjects were white males
(Table 1). The majority of subjects had sporadic ALS (69/76;
91%) with a mean time from diagnosis of 11.1 months and a mean
time from onset of muscle weakness of 19.4 months; the mean time
from onset of muscle weakness varied considerably between these
cohorts (Table 1). Fifty-nine (78%) subjects (35/40 and 24/36 in
the SD and RD cohorts, respectively) were taking riluzole.
Safety
Overall, ozanezumab was well tolerated. Forty-seven (62%)
subjects across all cohorts (35/57 [61%] on active treatment, 12/
19 [63%] on placebo) reported at least one AE (Table 2). The
proportion of subjects who reported $1 AE in the ozanezumab
groups was similar when compared with the placebo group (61%
and 63%, respectively) although the overall incidence of AEs in the
RD 2.5 mg/kg and 15 mg/kg ozanezumab groups (78% and 89%
of subjects with any AE, respectively) was higher than in the RD
placebo group (56%) and the RD 0.5 mg/kg ozanezumab group
(44%). Most AEs were of mild or moderate intensity as judged by
the investigator. Seven (9%) subjects (5/57 [8.8%] on active
treatment, 2/19 [10.5%] on placebo) reported eight AEs of severe
intensity. Among the severe AEs, three subjects experienced severe
headache. Two of these were in placebo groups. The third subject
reported onset of headache 9 days after receiving the first dose of
ozanezumab (RD 2.5 mg/kg group); this was resolved after 6 days
and was not considered related to treatment. Another subject
experienced severe dysphagia (RD 15 mg/kg ozanezumab), which
was unresolved at the end of the study and considered not related
to study drug. The remaining four severe AEs in three subjects
were classed as SAEs.
Thirty-two AEs (29 mild, one moderate, one severe, and one of
unknown severity), that were considered possibly related to the
study medication, were reported by eight subjects (Table 2). None
resulted in withdrawal from the study. Most common AEs
(reported in $4 subjects across all cohorts) were back pain,
bronchitis, fall, headache and procedural pain at biopsy site
(Table 2). AEs in the cardiac disorders category were reported in
four subjects. One of these, sinus tachycardia of mild intensity, was
considered possibly related to investigational product (RD
2.5 mg/kg ozanezumab). Other events, not considered related to
study drug, included ventricular extrasystoles (SD 5 mg/kg
ozanezumab), which resolved after 2 hours, with the subject
remaining asymptomatic with no findings of clinical concern on
Holter monitoring; second degree atrioventricular block (RD
2.5 mg/kg ozanezumab); and cardiac arrest and cardio-respirato-
ry arrest, as described under SAEs below.
Six SAEs were reported in three subjects receiving ozanezumab,
all considered by the investigators as unrelated to study
medication. One subject (SD 15 mg/kg ozanezumab) suffered a
head injury after an accidental fall, which led to hospitalization
and ultimately resolved. The second subject (SD 5 mg/kg
ozanezumab) experienced excess bronchial secretions resulting in
hospitalization, and later died from respiratory failure, 17 weeks
after the dosing. The third subject (RD 2.5 mg/kg ozanezumab)
was hospitalized for abdominal pain, for which the etiology
remained elusive; this subject later died from cardiac arrest and
cardio-respiratory arrest 10.5 weeks after the second dose.
The events common to ALS showed no patterns of reporting to
suggest an adverse drug effect on the underlying condition. The
most frequently reported event common to ALS was weakness,
occurring in 8/19 (42%) and 19/57 (33%) subjects in the placebo
and ozanezumab groups, respectively.
Figure 1. Subject disposition flow diagram for Parts 1 and 2. N, total number of subjects in group; n, number of subjects in category; PK,
pharmacokinetics; SAE, serious adverse events. *Two doses, received 4 weeks apart.
doi:10.1371/journal.pone.0097803.g001
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Analysis of ECG data showed that the proportion of subjects
with QTcB or QTcF values in the lowest category of potential
clinical importance (absolute QTc.450 msec and up to 480 msec
or QTc change from baseline .30 msec and up to 60 msec) was
slightly greater in the ozanezumab RD 15 mg/kg dose group
compared with the other RD groups (Table S4). An absolute QTc
value .500 msec (or .480 msec) or a QTc change from baseline
.60 msec was not observed in any subject at any point.
Evaluation of these data demonstrated no clear patterns indicative
of a treatment effect on ECG parameters.
Vital signs showed no notable differences between ozanezumab
groups and placebo. No clinically significant safety laboratory
findings were reported by the investigator. However, there were
findings of potential clinical importance (PCI). Three subjects
experienced elevations in liver function tests; one subject (SD
placebo) had an alanine aminotransferase (ALT) value approxi-
mately 26 the upper limit of normal (ULN), elevated aspartate
aminotransferase (aspartate aminotransferase [AST]; ,26ULN)
and elevated gamma-glutamyl transpeptidase (GGT; approxi-
mately 36 ULN), on Day 22. A second subject (SD 5 mg/kg
ozanezumab) had elevated total bilirubin (approximately 26
ULN) on Day 50, and a third subject (RD 2.5 mg/kg
ozanezumab) had an elevated ALT value (approximately 36
ULN), accompanied by elevations of AST (,26ULN) and GGT
(approximately 36 ULN). Seven subjects had elevated glucose
levels of PCI, all of whom received ozanezumab; these elevations
occurred at least 1 week after dosing in five of these subjects.
Isolated cases of hyperglycemia were seen in patients who received
ozanezumab. The findings were based on random blood glucose
samples. None of the elevated glucose values were considered
clinically significant by the investigator and were not reported as
AEs. There was no apparent dose-response. Mild hematological
abnormalities occurred in four subjects receiving ozanezumab.
However, these were not considered clinically significant. Elevated
creatine kinase levels were observed in a number of subjects across
all treatment groups but this is a common finding in patients with
ALS and was not considered clinically relevant. Urinalysis findings
raised no safety concerns. See Results S1 for additional details of
laboratory findings.
Changes in heart rate were reported for a small number of
subjects but none were considered clinically significant. Two
subjects experienced changes in blood pressure that were recorded
as AEs. However, neither event was considered related to the
study drug.
Pharmacokinetics
Peak plasma ozanezumab concentrations were generally
observed at the end of infusion. Cmax and AUC typically increased
proportional to dose, while concentrations declined in a bi-
exponential fashion, with a terminal elimination half-life of
approximately 20 days (Table 3 and Figure 2).
Immunogenicity
In one subject (RD 15 mg/kg ozanezumab) anti-ozanezumab
antibodies were detected at Week 20 (weak titer of 2), having
shown negative results at all previous time points. No AEs
indicative of an immune-related reaction were reported for this
subject around the time of the positive antibody response. No anti-
ozanezumab antibodies were detected in any other subject.
Functional endpoints (clinical and electrophysiological)
There were no apparent treatment effects on ALSFRS-R slope,
% of predicted SVC percentage change from screening or MMT
slope following treatment with ozanezumab compared with
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placebo. However, a numerical difference in favor of ozanezumab
versus placebo was observed in the RD 15 mg/kg group for each
endpoint (Tables S5 and S6).
In MUNE data analysis, no trends between ozanezumab groups
and placebo were observed (Table S6).
Biomarkers
There was no evidence of a pharmacological response with
ozanezumab treatment on protein or RNA biomarkers.
Measurement of Nogo-A and ozanezumab using IHC staining
of muscle biopsies suggested co-localization of the drug at the site
of action in skeletal muscle. Co-localization followed a similar
trend to ozanezumab levels in muscle, suggesting that this was
related to exposure. Greater than 90% co-localization was
observed with the 15 mg/kg dose, 8 days after dosing, with levels
dropping below 90% at 3–4 weeks post-dose (Figure 3).
Pharmacokinetic/functional endpoint relationship
Following graphical exploration of a potential exposure-
response relationship of ozanezumab for ALSFRS-R score
(monthly rate of decline) at each post-baseline visit, no PK/
functional endpoint relationship was identified.
Discussion
The effort to develop new treatments for ALS has led to
repeated failure since the demonstration that riluzole extended
survival.[3] Despite initially encouraging results from a Phase II
trial, which suggested beneficial effects on ALSFRS-R and
survival,[27] the recent negative results of the dexpramipexole
Phase III study is yet another disappointing example.[28] Thus,
there is still an urgent need for new treatments for ALS. A number
of compounds targeting different aspects of ALS pathogenesis are
Figure 2. Mean plasma ozanezumab concentration-time profiles following single (A) or two (B) IV infusions of ozanezumab.
doi:10.1371/journal.pone.0097803.g002
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Figure 3. Co-localization of membrane Nogo-A with ozanezumab in skeletal muscle of individual subjects. A. Triplicate readings are
provided from biopsies in Cohort 7 and 8 (single reading from Cohort 5) dose 2 +D22–26, biopsy taken 22–26 days after the second dose; dose 1 +
24H, biopsy taken 24 hours after first dose. B. Nogo-A (red), ozanezumab (green) and co-localization (yellow), in muscle biopsy, 24 hours post-dose.
doi:10.1371/journal.pone.0097803.g003
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currently being investigated. This was the first study in humans of
ozanezumab, a monoclonal antibody targeting Nogo-A.
Generally the baseline characteristics were similar between
treatment groups, however, as the inclusion criteria permitted a
history of muscle weakness of up to 60 months; 8/76 (11%)
patients reported having muscle weakness for 36 months or longer.
This could have caused a bias towards long-term survivors and
since the patient cohorts were small, the mean disease duration
varied considerably between these cohorts.
Ozanezumab was generally well tolerated at single doses of
0.01–15 mg/kg and two repeat doses of 0.5–15 mg/kg, with no
adverse drug effects on the underlying condition.
Although there was no clear relationship between reported AEs
and increasing doses of ozanezumab, the overall incidence of AEs
was numerically higher in the two higher dose RD cohorts
compared with placebo and the lowest dose RD cohort. Despite
the higher incidence of AEs in the RD cohorts, proportions of
mild, moderate and severe AEs were comparable. SAEs and
deaths were not attributed to the study drug, though one cardiac
non-serious AE (mild sinus tachycardia) was considered possibly
related. There were no clinically significant safety laboratory
findings and no clear patterns indicative of a treatment effect on
ECG parameters or vital signs.
Following IV infusion, the plasma PK characteristics of
ozanezumab were generally consistent with those of a humanized
immunoglobulin G monoclonal antibody. One observation of note
was the approximate 2-fold difference between SD and RD (first
dose) ozanezumab 15 mg/kg in average Cmax and AUC values.
Examination of the individual data suggested no overlap in values
between the two cohorts. However, detailed investigations of drug
substance, subject demographics, individual dosing records, and
the PK plasma sample assay methodology revealed no explanation
for this difference. Consequently, the difference appeared to be
genuine, and possibly attributed to between-cohort variability.
This study was not statistically powered to detect changes in
functional (clinical and electrophysiological) endpoints. Despite
this, and despite subjects receiving only one or two doses each, a
trend was observed for clinical endpoints such as ALSFRS-R,
SVC, and MMT, which possibly suggested a response in the
highest dose cohorts. Trends observed should be interpreted with
great caution given the small sample size, and other studies will be
required to confirm and further investigate these trends. The
relationship between ozanezumab administration and pharmaco-
logical signal on protein or RNA requires further investigation; the
current study may have been too short to detect such responses. In
future studies, optimum time points, treatment times, and analysis
methods will need to be established.
IHC staining of muscle biopsies suggested that there were dose-
dependent changes in ozanezumab quantification and detection
and that ozanezumab distributed and co-localized with Nogo-A at
the site of action in skeletal muscle. Following the full distribution
of ozanezumab to muscle tissue and peak co-localization
approximately 1 week after dosing, the percentage of co-
localisation appeared to be related to levels of ozanezumab,
suggesting a possible relationship with exposure.
Overall, ozanezumab was well tolerated and PK parameters
were generally consistent with those of humanized monoclonal
antibodies. The trends observed on functional endpoints in the
present study, along with the co-localization of ozanezumab in
skeletal muscle, are encouraging; these observations, along with
the lack of emerging safety signals, support future studies of
ozanezumab in this devastating disease, and a Phase II study of
efficacy and safety of ozanezumab (NCT01753076) is currently
underway.
Supporting Information
Table S1 Assessment schedules for Part 1. AE, adverse
event; ALSFRS-R, amyotrophic lateral sclerosis functional rating
scale-revised; ECG, electrocardiogram; FU, follow-up; MUNE,
motor unit number estimation; PK, pharmacokinetic; SAE,
serious adverse event. *The precise timing of safety, functional
assessments, and PK blood sampling may have been altered
during the course of the study based on emerging data. If the
profile indicated that more sampling or assessments were needed,
additional time points were to be added. Study assessments to
follow PK sampling at end of the infusion. (The 1-hour PK sample
was collected directly at the end of the infusion, Cohorts 2–8).
{Only SAEs related to study participation were collected prior to
the start of the investigational product. Once the investigational
product infusion began, all AEs and SAEs were collected until the
last FU visit. {Continuous Lead II ECG commenced approxi-
mately 1 hour pre-dose on Day 1 until 24 hours post-dose.
1Muscle biopsies, which were voluntary collections in Cohort 3
(1 mg/kg) and required collections in Cohort 5 (15 mg/kg) were
collected pre-dose and at Week 4. The pre-dose muscle biopsy was
only to be done when the subject had passed all screening
assessments and eligibility had been reconfirmed. This meant the
pre-dose biopsy could be done at any appropriate time before Day
1. Blood samples at pre-dose and at Week 4 were collected
regardless of whether or not a muscle biopsy was to be taken. The
number and schedule of FU visits after Week 12 for each subject
was to vary depending on plasma concentrations of ozanezumab
reaching a low enough level to allow a final blood sample to have
been assayed for immunogenicity.
(DOCX)
Table S2 Assessment schedules for Part 2. AE, adverse
event; ALSFRS-R, amyotrophic lateral sclerosis functional rating
scale-revised; ECG, electrocardiogram; FU, follow-up; MUNE,
motor unit number estimation; PK, pharmacokinetic; SAE,
serious adverse event. *The precise timing of safety, functional
assessments and PK blood sampling may have been altered during
the course of the study based on emerging data. If the profile
indicated that more sampling or assessments were needed,
additional time points were to be added. Study assessments to
follow PK sampling at end of infusion. (The 1-hour PK sample was
collected directly at the end of the infusion, Cohorts 2–8). {Only
SAEs related to study participation were collected prior to the start
of the investigational product. Once the investigational product
infusion began, all AEs and SAEs were collected until the last FU
visit. {Continuous Lead II ECG commenced approximately
1 hour pre-dose until 24 hours post-Dose 1 and for 6 hours
post-Dose 2. 1In cohorts 6 and 7 the pre-dose muscle biopsy and
blood sample were only done when the subject had passed all
screening assessments and eligibility had been reconfirmed. This
meant the pre-dose biopsy and blood sample could be done at any
appropriate time before Day 1. The post-dose muscle biopsy and
blood sample were scheduled for collection at Week 8 (unless
emerging data suggested the post-dose muscle biopsy and blood
sample should have been collected at an alternative week). In
cohort 8, muscle biopsies and blood sample were collected from
subjects at pre-dose and at one time point after the first dose.
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Subjects were assigned for a post-dose muscle biopsy and blood
sample collection at either Day 1 (+24 hours), Day 8 or Week 4
(Day 22–24) based on subject preference determined at screening
(see Section 7.3). If the subject had the Day 1 (+24 hours)
collection then the pre-dose muscle biopsy and blood sample were
collected at least 8 days before Day 1. #The number and schedule
of FU visits after Week 16 for each subject varied depending on
plasma concentrations of ozanezumab reaching a low enough level
to allow a final blood sample to have been taken for
immunogenicity assays.
(DOCX)
Table S3 Primer and probe sets used in biomarker
analyses.
(DOCX)
Table S4 Summary of QTc values of potential clinical
importance at any visit post-baseline. n, number of
subjects; SD, single dose; RD, repeated dose. *Two doses, received
4 weeks apart.
(DOCX)
Table S5 Summary of ALSFRS-R and MMT analyses. n,
number of evaluable subjects; RD, repeat dose; SD, single dose;
SE, standard error. ALSFRS-R, ALS functional rating scale-
revised; CI, confidence interval; MMT, manual muscle strength
test; Measured at Week 12 for SD study, Week 16 for RD study.
*Two doses, received 4 weeks apart.
(DOCX)
Table S6 Summary of SVC and MUNE analyses. CI,
confidence interval; MUNE, motor unit number estimation; n,
number of evaluable subjects; RD, repeat dose; SD, single dose;
SE, standard error; SMUP, single motor unit potential; SVC, slow
inspiratory vital capacity. Measured at Week 12 for SD study,
Week 16 for RD study. *Two doses, received 4 weeks apart.
(DOCX)
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(DOC)
Results S1
(DOCX)
Checklist S1 CONSORT checklist.
(DOC)
Protocol S1 Redacted protocol.
(PDF)
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